- Home
- HSHP vs AVIR Comparison
HSHP vs AVIR Comparison
Compare HSHP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- AVIR
- Stock Information
- Founded
- HSHP 2021
- AVIR 2012
- Country
- HSHP Bermuda
- AVIR United States
- Employees
- HSHP N/A
- AVIR N/A
- Industry
- HSHP
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- HSHP
- AVIR Health Care
- Exchange
- HSHP Nasdaq
- AVIR Nasdaq
- Market Cap
- HSHP 231.4M
- AVIR 251.7M
- IPO Year
- HSHP 2023
- AVIR 2020
- Fundamental
- Price
- HSHP $5.34
- AVIR $3.09
- Analyst Decision
- HSHP
- AVIR Hold
- Analyst Count
- HSHP 0
- AVIR 1
- Target Price
- HSHP N/A
- AVIR $6.88
- AVG Volume (30 Days)
- HSHP 168.3K
- AVIR 329.3K
- Earning Date
- HSHP 02-20-2025
- AVIR 03-03-2025
- Dividend Yield
- HSHP 8.98%
- AVIR N/A
- EPS Growth
- HSHP 1125.21
- AVIR N/A
- EPS
- HSHP 0.48
- AVIR N/A
- Revenue
- HSHP $123,580,000.00
- AVIR N/A
- Revenue This Year
- HSHP $252.71
- AVIR N/A
- Revenue Next Year
- HSHP $11.04
- AVIR N/A
- P/E Ratio
- HSHP $11.33
- AVIR N/A
- Revenue Growth
- HSHP 236.40
- AVIR N/A
- 52 Week Low
- HSHP $4.48
- AVIR $2.75
- 52 Week High
- HSHP $9.76
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- HSHP 60.88
- AVIR 48.26
- Support Level
- HSHP $4.74
- AVIR $3.04
- Resistance Level
- HSHP $5.68
- AVIR $3.25
- Average True Range (ATR)
- HSHP 0.17
- AVIR 0.13
- MACD
- HSHP 0.09
- AVIR 0.01
- Stochastic Oscillator
- HSHP 70.31
- AVIR 54.29
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).